## Raymond John Playford

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7772533/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Newly identified genetic risk variants for celiac disease related to the immune response. Nature Genetics, 2008, 40, 395-402.	21.4	599
2	A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nature Genetics, 2007, 39, 827-829.	21.4	592
3	CAMPYLOBACTER PYLORI AND DUODENAL ULCERS: THE GASTRIN LINK. Lancet, The, 1989, 333, 1167-1168.	13.7	333
4	Colostrum and milk-derived peptide growth factors for the treatment of gastrointestinal disorders. American Journal of Clinical Nutrition, 2000, 72, 5-14.	4.7	330
5	Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet, The, 2005, 365, 1794-1796.	13.7	305
6	Epidermal Growth Factor Enemas with Oral Mesalamine for Mild-to-Moderate Left-Sided Ulcerative Colitis or Proctitis. New England Journal of Medicine, 2003, 349, 350-357.	27.0	296
7	Characterization and Clinical Application of Human CD34 <sup>+</sup> Stem/Progenitor Cell Populations Mobilized into the Blood by Granulocyte Colonyâ€Stimulating Factor. Stem Cells, 2006, 24, 1822-1830.	3.2	267
8	Reprogramming of intestinal differentiation and intercalary regeneration in <i>Cdx2</i> mutant mice. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 7318-7323.	7.1	262
9	Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology, 1995, 108, 108-116.	1.3	251
10	New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett's oesophagus. Gut, 2006, 55, 442-442.	12.1	222
11	Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 2137-2142.	7.1	168
12	The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract Gut, 1996, 39, 262-266.	12.1	150
13	Synergistic enhancement of Toll-like receptor responses by NOD1 activation. European Journal of Immunology, 2005, 35, 2471-2476.	2.9	135
14	Bovine colostrum is a health food supplement which prevents NSAID induced gut damage. Gut, 1999, 44, 653-658.	12.1	126
15	Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease. , 1998, 185, 413-418.		121
16	The nutriceutical bovine colostrum truncates the increase in gut permeability caused by heavy exercise in athletes. American Journal of Physiology - Renal Physiology, 2011, 300, G477-G484.	3.4	118
17	Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2316-2321.	7.1	117
18	Epidermal growth factor is digested to smaller, less active forms in acidic gastric juice. Gastroenterology, 1995, 108, 92-101.	1.3	111

#	Article	IF	CITATIONS
19	Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn's disease. Gut, 2005, 54, 1553-1557.	12.1	111
20	Effect of luminal growth factor preservation on intestinal growth. Lancet, The, 1993, 341, 843-848.	13.7	107
21	Comparison of cytokine modulation by natural peroxisome proliferator–activated receptor γ ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells—potential for dietary modulation of peroxisome proliferator–activated receptor γ in intestinal inflammation. American lournal of Clinical Nutrition. 2008. 87. 939-948.	4.7	107
22	Combined Intestinal Trefoil Factor and Epidermal Growth Factor is Prophylactic against Indomethacin-Induced Gastric Damage in the Rat. Clinical Science, 1995, 88, 401-403.	4.3	102
23	Bovine Colostrum: Its Constituents and Uses. Nutrients, 2021, 13, 265.	4.1	102
24	Genetic Variation in Myosin IXB Is Associated With Ulcerative Colitis. Gastroenterology, 2006, 131, 1768-1774.	1.3	95
25	Peptides and gastrointestinal mucosal integrity Gut, 1995, 37, 595-597.	12.1	92
26	Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clinical Science, 2001, 100, 627-633.	4.3	90
27	Effects of Mouse and Human Lipocalin Homologues 24p3/lcn2 and Neutrophil Gelatinase–Associated Lipocalin on Gastrointestinal Mucosal Integrity and Repair. Gastroenterology, 2006, 131, 809-817.	1.3	90
28	Why is epidermal growth factor present in the gut lumen?. Gut, 1996, 38, 303-305.	12.1	89
29	Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut, 2007, 56, 168-175.	12.1	88
30	Probiotics in inflammatory bowel disease: is it all gut flora modulation?. Gut, 2004, 53, 620-622.	12.1	83
31	Use of the â€~nutriceutical', bovine colostrum, for the treatment of distal colitis: results from an initial study. Alimentary Pharmacology and Therapeutics, 2002, 16, 1917-1922.	3.7	79
32	A common CTLA4 haplotype associated with coeliac disease. European Journal of Human Genetics, 2005, 13, 440-444.	2.8	76
33	Prophylactic Use of Epidermal Growth Factor Reduces Ischemia/Reperfusion Intestinal Damage. American Journal of Pathology, 2002, 161, 373-379.	3.8	73
34	Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. , 1998, 185, 153-158.		72
35	Bioactive natural compounds for the treatment of gastrointestinal disorders. Clinical Science, 2003, 104, 547-556.	4.3	72
36	Modulation of dendritic cell phenotype and functionin an <i>in vitro </i> model of the intestinal epithelium. European Journal of Immunology, 2006, 36, 864-874.	2.9	71

RAYMOND JOHN PLAYFORD

#	Article	IF	CITATIONS
37	Preliminary report: role of peptide YY in defence against diarrhoea. Lancet, The, 1990, 335, 1555-1557.	13.7	69
38	Reparative properties of a commercial fish protein hydrolysate preparation. Gut, 2005, 54, 775-781.	12.1	69
39	The trefoil peptide TFF1 inhibits the growth of the human gastric adenocarcinoma cell line AGS. , 1999, 188, 312-317.		68
40	Peptide gene expression in gastrointestinal mucosal ulceration: ordered sequence or redundancy?. Gut, 2000, 46, 286-292.	12.1	68
41	Gastrointestinal cell proliferation and crypt fission are separate but complementary means of increasing tissue mass following infusion of epidermal growth factor in rats. Gut, 2001, 48, 803-807.	12.1	67
42	Intestinal fatty acid-binding protein and gut permeability responses to exercise. European Journal of Applied Physiology, 2017, 117, 931-941.	2.5	62
43	Human Pancreatic Secretory Trypsin Inhibitor. Digestion, 1998, 59, 167-174.	2.3	58
44	Lack of association of MYO9B genetic variants with coeliac disease in a British cohort. Gut, 2006, 55, 969-972.	12.1	58
45	Zinc carnosine works with bovine colostrum in truncating heavy exercise–induced increase in gut permeability in healthy volunteers. American Journal of Clinical Nutrition, 2016, 104, 526-536.	4.7	57
46	Bismuth induced encephalopathy caused by tri potassium dicitrato bismuthate in a patient with chronic renal failure Gut, 1990, 31, 359-360.	12.1	55
47	Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK. Alimentary Pharmacology and Therapeutics, 2003, 17, 1319-1324.	3.7	54
48	Integration of <i>ERG</i> gene mapping and geneâ€expression profiling identifies distinct categories of human prostate cancer. BJU International, 2009, 103, 1256-1269.	2.5	54
49	Suppression of Helicobacter pylori reduces gastrin releasing peptide stimulated gastrin release in duodenal ulcer patients Gut, 1992, 33, 601-603.	12.1	52
50	Trial of trefoil factor 3 enemas, in combination with oral 5â€aminosalicylic acid, for the treatment of mildâ€ŧoâ€moderate leftâ€sided ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2005, 21, 1357-1364.	3.7	52
51	Co-administration of the health food supplement, bovine colostrum, reduces the acute non-steroidal anti-inflammatory drug-induced increase in intestinal permeability. Clinical Science, 2001, 100, 627.	4.3	51
52	Bone Marrow–Derived Stromal Cells Express Lineage-Related Messenger RNA Species. Cancer Research, 2006, 66, 1265-1269.	0.9	51
53	Ten years' experience of screening patients with Barrett's oesophagus in a university teaching hospital. Gut, 1997, 41, 303-307.	12.1	47
54	The mucous neck cell in the human gastric corpus: a distinctive, functional cell lineage. Journal of Pathology, 1999, 187, 331-337.	4.5	46

RAYMOND JOHN PLAYFORD

#	Article	IF	CITATIONS
55	Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides, 2004, 25, 793-801.	2.4	46
56	Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?. Gut, 2006, 55, 6-8.	12.1	46
57	Clinical trial: protective effect of a commercial fish protein hydrolysate against indomethacin (NSAID)â€induced small intestinal injury. Alimentary Pharmacology and Therapeutics, 2008, 28, 799-804.	3.7	46
58	Effect of Ectopic Expression of Rat Trefoil Factor Family 3 (Intestinal Trefoil Factor) in the Jejunum of Transgenic Mice. Journal of Biological Chemistry, 2001, 276, 24088-24096.	3.4	45
59	Epidermal growth factor reduces multiorgan failure induced by thioacetamide. Gut, 2001, 48, 34-40.	12.1	44
60	Effects of keratinocyte growth factor (KGF) on gut growth and repair. , 1998, 184, 316-322.		43
61	GERD 2003 – A Consensus on the Way Ahead. Digestion, 2003, 67, 111-117.	2.3	41
62	Pancreatic secretory trypsin inhibitor in gastrointestinal mucosa and gastric juice Gut, 1990, 31, 1318-1323.	12.1	40
63	Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Trends in Pharmacological Sciences, 1996, 17, 436-438.	8.7	38
64	Dietary microparticles implicated in Crohn's disease can impair macrophage phagocytic activity and act as adjuvants in the presence of bacterial stimuli. Inflammation Research, 2007, 56, 353-361.	4.0	38
65	Luminal Epidermal Growth Factor is Trophic to the Small Intestine of Parenterally Fed Rats. Clinical Science, 1995, 89, 117-120.	4.3	37
66	Comparison of the Effects of Transforming Growth Factor $\hat{I}_{\pm}$ and Epidermal Growth Factor on Gastrointestinal Proliferation and Hormone Release. Digestion, 1996, 57, 362-367.	2.3	31
67	Potency and stability of C terminal truncated human epidermal growth factor. Gut, 2000, 47, 622-627.	12.1	30
68	Interfering with interferons in inflammatory bowel disease. Gut, 2005, 55, 1071-1073.	12.1	29
69	Intestinal Growth in Parenterallyâ€Fed Rats Induced by the Combined Effects of Glucagonâ€ŀike Peptide 2 and Epidermal Growth Factor. Journal of Parenteral and Enteral Nutrition, 2005, 29, 248-254.	2.6	27
70	Whipple's disease complicated by a retinal Jarisch-Herxheimer reaction: a case report Gut, 1992, 33, 132-134.	12.1	26
71	Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol Gut, 1991, 32, 1396-1400.	12.1	25
72	Pancreatic secretory trypsin inhibitor is a major motogenic and protective factor in human breast milk. American Journal of Physiology - Renal Physiology, 2009, 296, G697-G703.	3.4	25

#	Article	IF	CITATIONS
73	Use of the Alpha-Glucosidase Inhibitor Acarbose in Patients with â€~Middleton Syndrome': Normal Gastric Anatomy But with Accelerated Gastric Emptying Causing Postprandial Reactive Hypoglycemia and Diarrhea. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 403-404.	1.7	25
74	Intestinal protective effect of a commercial fish protein hydrolysate preparation. Regulatory Peptides, 2009, 155, 105-109.	1.9	23
75	Marked variability in bioactivity between commercially available bovine colostrum for human use; implications for clinical trials. PLoS ONE, 2020, 15, e0234719.	2.5	22
76	Dose-Dependent Effects of Fentanyl on Indomethacin-Induced Gastric Damage. Digestion, 1991, 49, 198-203.	2.3	21
77	Growth factors and trefoil peptides in gastrointestinal health and disease. Current Opinion in Pharmacology, 2004, 4, 567-571.	3.5	21
78	Detection of muramyl dipeptide-sensing pathway defects in patients with Crohn's disease. Inflammatory Bowel Diseases, 2006, 12, 598-605.	1.9	21
79	Dimethyloxalyglycine stimulates the early stages of gastrointestinal repair processes through VEGF-dependent mechanisms. Laboratory Investigation, 2011, 91, 1684-1694.	3.7	20
80	Reparative properties of the traditional Chinese medicine <i>Cordyceps sinensis</i> (Chinese) Tj ETQq0 0 0 rgBT Journal of Nutrition, 2011, 105, 1303-1310.	/Overlock 2.3	10 Tf 50 467 20
81	Effect of chymotrypsin on human cholecystokinin release: use of clostripain in the validation of a new radioimmunoassay. Regulatory Peptides, 1992, 40, 1-12.	1.9	19
82	Gastroprotective effects of oral nucleotide administration. Gut, 2006, 55, 165-171.	12.1	19
83	Pancreatic secretory trypsin inhibitor causes autocrine-mediated migration and invasion in bladder cancer and phosphorylates the EGF receptor, Akt2 and Akt3, and ERK1 and ERK2. American Journal of Physiology - Renal Physiology, 2013, 305, F382-F389.	2.7	19
84	Influence of inflammation and atrophy on pancreatic secretory trypsin inhibitor levels within the gastric mucosa. Gastroenterology, 1994, 106, 735-741.	1.3	17
85	Nitric oxide regulates the release of somatostatin from cultured gastric rabbit primary D-cells. Gastroenterology, 2002, 123, 566-576.	1.3	17
86	Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clinical Science, 2006, 110, 563-573.	4.3	17
87	NOD2 activity modulates the phenotype of LPS-stimulated dendritic cells to promote the development of T-helper type 2-like lymphocytes — Possible implications for NOD2-associated Crohn's disease. Journal of Crohn's and Colitis, 2007, 1, 106-115.	1.3	17
88	Oral bovine colostrum supplementation does not increase circulating insulin-like growth factor-1 concentration in healthy adults: results from short- and long-term administration studies. European Journal of Nutrition, 2020, 59, 1473-1479.	3.9	15
89	Does the response of the intestinal epithelium to keratinocyte growth factor vary according to the method of administration?. Regulatory Peptides, 2000, 87, 83-90.	1.9	14
90	Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. European Journal of Immunology, 2006, 36, 1629-1635.	2.9	14

#	Article	IF	CITATIONS
91	Pasteurized Chicken Egg Powder Stimulates Proliferation and Migration of ACS, RIE1, and Caco-2 Cells and Reduces NSAID-Induced Injury in Mice and Colitis in Rats. Journal of Nutrition, 2020, 150, 1434-1442.	2.9	14
92	Liver biopsy under ultrasound control: implications for training in the Calman era. Gut, 1999, 45, 628-629.	12.1	13
93	Endoscopic surveillance of patients with Barrett's oesophagus. Gut, 2002, 51, 314-315.	12.1	13
94	Human transforming growth factor alpha (TGF-alpha) is digested to a smaller (1-43), less biologically active, form in acidic gastric juice. Gut, 2002, 51, 787-792.	12.1	12
95	Human Pancreatic Secretory Trypsin Inhibitor Stabilizes Intestinal Mucosa against Noxious Agents. American Journal of Pathology, 2007, 171, 1462-1473.	3.8	12
96	Effects of Bovine Colostrum with or without Egg on In Vitro Bacterial-Induced Intestinal Damage with Relevance for SIBO and Infectious Diarrhea. Nutrients, 2021, 13, 1024.	4.1	11
97	Right ventricular pacing wire thrombus presenting as pyrexia of unknown origin. Clinical Cardiology, 1989, 12, 106-108.	1.8	10
98	Hypergastrinaemia: a new mechanism. Lancet, The, 1991, 338, 410-411.	13.7	10
99	Growth factors and gut function. Proceedings of the Nutrition Society, 1998, 57, 403-408.	1.0	10
100	Does Helicobacter pylori Eradication Reduce the Long-term Requirements for Acid Suppressants in Patients with a History of Peptic Ulcer Disease in General Practice? Results from a Four-Year Longitudinal Study. Scandinavian Journal of Gastroenterology, 2002, 37, 144-147.	1.5	10
101	Trefoil factor family peptides enhance cell migration by increasing cellular osmotic permeability and aquaporin 3 levels. FASEB Journal, 2018, 32, 1017-1024.	0.5	10
102	Review: Insulin resistance and mitochondrial dysfunction following severe burn injury. Peptides, 2020, 126, 170269.	2.4	10
103	pH-Dependent Secretion of Gastrin in Duodenal Ulcer Disease: Effect of Suppressing <i>Helicobacter pylori</i> . Digestion, 1992, 52, 173-178.	2.3	9
104	IL-1β stimulation of CCD-18co myofibroblasts enhances repair of epithelial monolayers through Wnt-5a. American Journal of Physiology - Renal Physiology, 2012, 303, G1270-G1278.	3.4	9
105	Pantoprazole, Prout and the proton pump. British Journal of Hospital Medicine, 1999, 60, 500-504.	0.2	7
106	Epidermal growth factor enemas are effective in the treatment of left-sided ulcarative colitis. Gastroenterology, 2001, 120, A11-A12.	1.3	7
107	Landscaper seeks remunerative position. Gut, 2001, 48, 594-595.	12.1	7
108	Effects of a panel of dietary lectins on cholecystokinin release in rats. American Journal of Physiology - Renal Physiology, 1997, 273, G946-G950.	3.4	6

#	Article	IF	CITATIONS
109	Cost Analysis of Breath Test versus Endoscopy for Dyspepsia. Digestion, 2002, 65, 207-212.	2.3	6
110	Pancreatic secretory trypsin inhibitor reduces multi-organ injury caused by gut ischemia/reperfusion in mice. PLoS ONE, 2020, 15, e0227059.	2.5	6
111	Effects of diet and the cholecystokinin antagonist; devazepide (L364, 718) on CCK mRNA, and tissue and plasma CCK concentrations. European Journal of Clinical Investigation, 1993, 23, 641-647.	3.4	5
112	Tales from the human crypt—intestinal stem cell repertoire and the origins of human cancer. , 1998, 185, 119-122.		5
113	TAME trial: a multi-arm phase II randomised trial of four novel interventions for malnutrition enteropathy in Zambia and Zimbabwe - a study protocol. BMJ Open, 2019, 9, e027548.	1.9	5
114	The Use of Bovine Colostrum in Medical Practice and Human Health: Current Evidence and Areas Requiring Further Examination. Nutrients, 2022, 14, 92.	4.1	5
115	Development of a two-site ELISA assay for the dimeric form of human TFF1. Peptides, 2004, 25, 731-736.	2.4	4
116	The value of surveillance and other unresolved issues in the management of Barrett's esophagus. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 60-61.	1.7	4
117	Oral zinc carnosine reduces multi-organ damage caused by gut ischemia/reperfusion in mice. Journal of Functional Foods, 2021, 78, 104361.	3.4	4
118	Intralesional Infiltrations of Cell-Free Filtrates Derived from Human Diabetic Tissues Delay the Healing Process and Recreate Diabetes Histopathological Changes in Healthy Rats. Frontiers in Clinical Diabetes and Healthcare, 2021, 2, .	0.8	4
119	9 Growth factors and ulcerative gastrointestinal disease. Bailliere's Clinical Gastroenterology, 1996, 10, 135-149.	0.9	3
120	Cytokines and Helicobacter pylori–a growth area Gut, 1996, 39, 881-882.	12.1	3
121	Growth factors in saliva. Lancet, The, 1997, 350, 369.	13.7	3
122	Liver biopsy under ultrasound control Reply. Gut, 2000, 47, 455-455.	12.1	3
123	Once you start, you can't stop. Lancet, The, 2002, 359, 226.	13.7	3
124	Methods to improve efficacy of orally administered bioactive peptides using bovine colostrum as an exemplar. PLoS ONE, 2021, 16, e0253422.	2.5	3
125	Protease Inhibitors Protect Bovine Colostrum or Chicken Egg Growth Factors from Pancreatic Enzyme Digestion in AGS Cells or Colitic Rats. Journal of Nutrition, 2021, 151, 3036-3044.	2.9	3
126	Epidermal growth factor and intestinal growth. Gastroenterology, 1995, 108, 1330-1331.	1.3	2

#	Article	IF	CITATIONS
127	Effects of growth factors and receptor blockade on gastrointestinal cancer. Gut, 2004, 53, 1059-1063.	12.1	2
128	What is the role of growth factors in IBD?. Inflammatory Bowel Diseases, 2008, 14, S119-S120.	1.9	2
129	Is glutamine required for the trophic effect of epidermal growth factor?. Surgery, 1995, 117, 355.	1.9	1
130	Surveillance for Barrett's oesophagus: is there light at the end of the metaplastic tunnel?. Journal of the Royal College of Surgeons of Edinburgh, 2003, 1, 152-156.	1.8	1
131	Accelerated exposure of phosphatidylserine on lymphocyte populations from patients with systemic lupus erythematosus or rheumatoid arthritis. Thrombosis and Haemostasis, 2005, 93, 989-992.	3.4	1
132	Specific protein supplementation using soya, casein or whey differentially affects regional gut growth and luminal growth factor bioactivity in rats; implications for the treatment of gut injury and stimulating repair. Food and Function, 2018, 9, 227-233.	4.6	1
133	Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. Journal of Pathology, 1998, 185, 153-158.	4.5	1
134	Intralesional Infiltrations of Arteriosclerotic Tissue Cells-Free Filtrate Reproduce Vascular Pathology in Healthy Recipient Rats. International Journal of Molecular Sciences, 2022, 23, 1511.	4.1	1
135	The Trefoil Peptide TFF1 Inhibits the Growth of the Human Gastric Adenocarcinoma Cell Line, AGS. Clinical Science, 1999, 96, 1P-1P.	0.0	0
136	Liver biopsy: "blind" or under ultrasound control Reply. Gut, 2001, 49, 157-158.	12.1	0
137	Homeobox genes: going for growth. Gut, 2002, 50, 447-448.	12.1	Ο
138	What is the role of growth factors in IBD?. Inflammatory Bowel Diseases, 2008, 14, S119-S120.	1.9	0
139	Growth Factors. , 2004, , 249-256.		0
140	Relevance of Growth Factors for the Gastrointestinal Tract and Other Organs. Nutraceutical Science and Technology, 2005, , 217-241.	0.0	0